Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for EYLEA® (aflibercept) Injection to treat Retinopathy of Prematurity (ROP) in preterm infants. The target action date for the FDA decision is February 11, 2023.
https://finance.yahoo.com/news/eylea-aflibercept-injection-sbla-treatment-110000734.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.